APR-246 + azacitidine
A18-15331
Phase 3 small_molecule completed
Quick answer
APR-246 + azacitidine for MDS is a Phase 3 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aprea Therapeutics
- Indication
- MDS
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed